Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03938246 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

Interventions

DRUG: TVB-2640 25 mg (US)
DRUG: TVB-2640 50 mg (US)
DRUG: Placebo (US)
DRUG: TVB-2640 50 mg (China)
DRUG: Placebo (China)
DRUG: TVB-2640 75 mg (US)

Sponsor

Sagimet Biosciences Inc.